Mankind Pharma IPO: Today is the last chance to invest in Mankind Pharma’s IPO, know whether investing is profitable or not
At the same time, there is no speed in the IPO from the retail investors, for whom the reserve quota is filled only 0.25 times. The company has offered 2,81,41,192 shares, out of which applications have been received for 2,45,19,352 shares. The company is aiming to raise Rs 4326.36 crore through the IPO.
price band fixed
Let us tell you that Mankind Pharma manufactures pregnancy test kits under the brand names Manforce Condom and Prega News. Mankind Pharma has fixed a price band of Rs 1026 to Rs 1080 per share. The company (Mankind Pharma) has allotted 1.2 crore shares to 77 funds at Rs 1080 per share. Mankind Pharma has raised Rs 1298 crore through anchor investors.
Till now the IPO has not filled even once. However, it is believed that most investors invest in IPOs only on the last day. Because the money gets blocked in their account. Through the IPO, the promoters and investors of the company are selling their stake in the offer for sale. After selling the shares under the offer for sale, the promoter’s stake in the company will come down from 79 per cent to 76.50 per cent.
Multibagger Stock: Amazing stock! ₹ 1 lakh investors get ₹ 12 crore, bumper bonus with 64000% return
Listing will be on 9th May
If you want to invest in Mankind Pharma IPO, then you will need at least Rs 14,040. There are 13 shares of the company in one lot. The allotment of shares can happen by May 3, 2023. The IPO has been proposed for listing on both BSE and NSE. The listing of Mankind Pharma’s IPO will be on the stock exchange by 9 May 2023. Half of the IPO is reserved for qualified institutional buyers. While 35 per cent is reserved for retail investors and 15 per cent for non-institutional buyers.
Will investing money be beneficial?
According to experts, due to expensive valuations, high debt and income not being used for business, gray market premiums will come down going forward. In such a situation, if an investor wants to invest in IPO for the long term, then he can earn good profits. Post listing, Mankind Pharma will join rivals like Abbott India, GlaxoSmithKline Pharma, Eris Lifescience. However, before investing in the stock market, you must talk to your financial advisor once. If you do not do this, you may have to suffer financially.
What is the condition of gray market
The gray market premium of this IPO is witnessing a decline today. It was trading at a premium of Rs 71 a few days ago. Thereafter it was at a premium of Rs 90. Whereas today it has come down to a premium of Rs.40. According to experts, the gray market premium of the issue is low relative to the offer size.
